Fine tuning of a type 1 interferon antagonist

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Urin, Victoria ^a   Levin, Doron ^a   Sharma, Nanaocha ^a   Harari, Daniel ^a   Schreiber, Gideon ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; INTERFERON RECEPTOR; INTERFERON TYPE 1 ANTAGONIST; STAT1 PROTEIN; STAT2 PROTEIN; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; MUTANT PROTEIN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL DENSITY; CELL SURVIVAL; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG MECHANISM; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CELL PROLIFERATION; DRUG EFFECTS; ENCEPHALOMYOCARDITIS VIRUS; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VESICULAR STOMATITIS INDIANA VIRUS; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENCEPHALOMYOCARDITIS VIRUS; GENE EXPRESSION; HUMANS; INTERFERON TYPE I; MICE, INBRED C57BL; MUTANT PROTEINS; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, INTERFERON ALPHA-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; VESICULAR STOMATITIS INDIANA VIRUS;

EID: 84941350329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130797     Document Type: Article

References (31)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proceedings of the Royal Society of London Series B, Containing papers of a Biological character Royal Society. 1957; 147(927):258-67. PMID: 13465720.
2. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology. 2006; 344(1):119-30. doi:10.1016/j.virol.2005.09.024 PMID: 16364743.
3. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nature reviews Immunology. 2005; 5(5):375-86. doi:10.1038/nri1604 PMID: 15864272.
4. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. Journal of viral hepatitis. 2003; 10(4):298-305. PMID: 12823597.
5. Goodin DS, Frohman EM, Garmany GP Jr., Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002; 58(2):169-78. PMID: 11805241.
6. Uze G, Schreiber G, Piehler J, Pellegrini S. The receptor of the type I interferon family. Current topics in microbiology and immunology. 2007; 316:71-95. PMID: 17969444.
7. Cohen B, Novick D, Barak S, Rubinstein M. Ligand-induced association of the type I interferon receptor components. Molecular and cellular biology. 1995; 15(8):4208-14. PMID: 7623815; PubMed Central PMCID: PMC230659.
8. Brierley MM, Fish EN. Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry. Journal of interferon & cytokine research: The official journal of the International Society for Interferon and Cytokine Research. 2002; 22(8):835-45. doi:10.1089/107999002760274845 PMID: 12396722.
9. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annual review of biochemistry. 1998; 67:227-64. doi:10.1146/annurev.biochem.67.1.227 PMID: 9759489.
10. Platanias LC, Fish EN. Signaling pathways activated by interferons. Experimental hematology. 1999; 27(11):1583-92. PMID: 10560905.
11. Levin D, Harari D, Schreiber G. Stochastic receptor expression determines cell fate upon interferon treatment. Molecular and cellular biology. 2011; 31(16):3252-66. doi:10.1128/MCB.05251-11 PMID: 21690295; PubMed Central PMCID: PMC3147786.
12. van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006; 25(3):361-72. doi:10.1016/j.immuni.2006.08.014 PMID: 16979568.
13. Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, Moolchan K, et al. Binding and activity of all human alpha interferon subtypes. Cytokine. 2011; 56(2):282-9. doi:10.1016/j.cyto.2011.07.019 PMID: 21856167.
14. Kalie E, Jaitin DA, Abramovich R, Schreiber G. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. The Journal of biological chemistry. 2007; 282(15):11602-11. doi:10.1074/jbc.M610115200 PMID: 17310065.
15. Pan M, Kalie E, Scaglione BJ, Raveche ES, Schreiber G, Langer JA. Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists. Biochemistry. 2008; 47 (46):12018-27. doi:10.1021/bi801588g PMID: 18937499.
16. Levin D, Schneider WM, Hoffmann HH, Yarden G, Busetto AG, Manor O, et al. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Science signaling. 2014; 7(327):ra50. doi:10.1126/scisignal.2004998 PMID: 24866020.
17. Roisman LC, Jaitin DA, Baker DP, Schreiber G. Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. Journal of molecular biology. 2005; 353(2):271-81. doi:10.1016/j.jmb.2005.08.042 PMID: 16171819.
18. Baruch K, Deczkowska A, David E, Castellano JM, Miller O, Kertser A, et al. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science. 2014; 346 (6205):89-93. doi:10.1126/science.1252945 PMID: 25147279.
19. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature. 2014; 511(7507):99-103. doi:10.1038/nature13489 PMID: 24990750.
20. Sandling JK, Garnier S, Sigurdsson S, Wang C, Nordmark G, Gunnarsson I, et al. A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE. European journal of human genetics: EJHG. 2011; 19(4):479-84. doi:10.1038/ejhg.2010.197 PMID: 21179067; PubMed Central PMCID: PMC3060320.
21. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 2014; 511(7511):601-5. doi:10.1038/nature13554 PMID: 25043006.
22. Harari D, Abramovich R, Zozulya A, Smith P, Pouly S, Koster M, et al. Bridging the species divide: Transgenic mice humanized for type-I interferon response. PloS one. 2014; 9(1):e84259. doi:10.1371/journal.pone.0084259 PMID: 24416207; PubMed Central PMCID: PMC3887009.
23. Harari D, Kuhn N, Abramovich R, Sasson K, Zozulya AL, Smith P, et al. Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis. The Journal of biological chemistry. 2014; 289(42):29014-29. doi:10.1074/jbc.M114.602474 PMID: 25193661; PubMed Central PMCID: PMC4200257.
24. Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N. ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic acids research. 2010; 38(Web Server issue):W529-33. doi:10.1093/nar/gkq399PMID: 20478830; PubMed Central PMCID: PMC2896094.
25. Piehler J, Thomas C, Garcia KC, Schreiber G. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunological reviews. 2012; 250(1):317-34. doi:10.1111/imr.12001 PMID: 23046138; PubMed Central PMCID: PMC3986811.
26. Coelho LF, Magno de Freitas Almeida G, Mennechet FJ, Blangy A, Uze G. Interferon-alpha and-beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102 (33):11917-22. doi:10.1073/pnas.0502188102 PMID: 16081539; PubMed Central PMCID: PMC1187968.
27. Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (Review). Oncology letters. 2011; 2 (4):583-9. doi:10.3892/ol.2011.300PMID: 22848232; PubMed Central PMCID: PMC3406435.
28. Cheon H, Borden EC, Stark GR. Interferons and their stimulated genes in the tumor microenvironment. Seminars in oncology. 2014; 41(2):156-73. doi:10.1053/j.seminoncol.2014.02.002 PMID: 24787290; PubMed Central PMCID: PMC4118773.
29. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 2011; 146(4):621-32. doi:10.1016/j.cell.2011.06.048 PMID: 21854986; PubMed Central PMCID: PMC3166218.
30. Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. The Journal of biological chemistry. 2008; 283(47):32925-36. doi:10.1074/jbc.M806019200PMID: 18801736.
31. Komurov K, Dursun S, Erdin S, Ram PT. NetWalker: a contextual network analysis tool for functional genomics. BMC genomics. 2012; 13:282. doi:10.1186/1471-2164-13-282 PMID: 22732065; PubMed Central PMCID: PMC3439272.